액체생검 시장 규모, 점유율, 동향 분석 보고서 : 바이오마커별, 기술별, 검체 유형별, 용도별, 임상 응용별, 최종 용도별, 제품별, 지역별, 부문별 예측(2026-2033년)

Liquid Biopsy Market Summary

The global liquid biopsy market size was estimated at USD 13.60 billion in 2025 and is projected to reach USD 32.57 billion by 2033, growing at a CAGR of 11.52% from 2026 to 2033. The industry is witnessing growth due to factors such as the growing prevalence of cancer, technological advancements in cancer diagnostics, and rising preference for minimally invasive cancer diagnostics.

Moreover, ongoing research for the development of liquid biopsy assays and tests, aided by the rising adoption and development of multi-cancer early detection tests, is providing a major opportunity for the growth of the overall market. Liquid biopsy is an advanced testing technology for the detection of genetic alterations related tumor. It has also been utilized to stratify tumors and deliver precise cancer treatment. For instance, in January 2023, Guardant Health received FDA approval for Guardant360 CDx, its liquid biopsy assay as companion diagnostics for ESR1 mutant breast cancer diagnosis. These recent innovations, advancements, and expansions in the industry promoting the use of liquid biopsy are driving the market.

Global Liquid Biopsy Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global liquid biopsy market report based on sample type, biomarker, technology, application, end use, clinical application, product, and region:

• Sample Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Blood Sample
• Others
• Biomarker Outlook (Revenue, USD Billion, 2021 - 2033)
• Circulating Tumor Cells (CTCs)
• Circulating Nucleic Acids
• Exosomes/Microvesicles
• Others
• Technology Outlook (Revenue, USD Billion, 2021 - 2033)
• Multi-gene parallel Analysis (NGS)
• Single Gene Analysis (PCR Microarrays)
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Cancer
  • Lung Cancer
  • Prostate Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Gastrointestinal Cancer
  • Others
• Reproductive Health
  • Others
• End Use Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospitals and Laboratories
• Specialty Clinics
• Academic and Research Centers
• Others
• Clinical Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Therapy Selection
• Treatment Monitoring
• Early Cancer Screening
• Recurrence Monitoring
• Others
• Product Outlook (Revenue, USD Billion, 2021 - 2033)
• Instruments
• Consumables Kits and Reagents
• Software and Services
• Regional Outlook (Revenue, USD Billion, 2021- 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation
  • 1.1.1. Market Definitions
• 1.2. Objectives
  • 1.2.1. OBJECTIVE - 1
  • 1.2.2. OBJECTIVE - 2
  • 1.2.3. OBJECTIVE - 3
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. PURCHASED DATABASE
  • 1.4.2. GVR'S INTERNAL DATABASE
  • 1.4.3. SECONDARY SOURCES
  • 1.4.4. PRIMARY RESEARCH
• 1.5. Information or Data Analysis
  • 1.5.1. DATA ANALYSIS MODELS
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. COMMODITY FLOW ANALYSIS
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers
  • 3.4.1. Increasing prevalence of cancer
  • 3.4.2. Growing geriatric population
  • 3.4.3. Technological advancements
  • 3.4.4. Increasing preference for noninvasive treatment
• 3.5. Market Restraint Analysis
  • 3.5.1. Patent expiry of blockbuster drugs prescribed
• 3.6. Business Environment Analysis
  • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis

Chapter 4. Sample Type Business Analysis

• 4.1. Liquid Biopsy Market: Type Movement Analysis
• 4.2. Blood Sample
  • 4.2.1. Blood Sample Market, 2021 - 2033 (USD Million)
• 4.3. Others
  • 4.3.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Biomarker Business Analysis

• 5.1. Liquid Biopsy Market: Biomarker Movement Analysis
• 5.2. Circulating Tumor Cells (CTCs)
  • 5.2.1. Circulating Tumor Cells (CTCs) Market, 2021 - 2033 (USD Million)
• 5.3. Circulating Nucleic Acids
  • 5.3.1. Circulating Nucleic Acids Market, 2021 - 2033 (USD Million)
• 5.4. Exosomes/Microvesicles
  • 5.4.1. Exosomes/Microvesicles Market, 2021 - 2033 (USD Million)
• 5.5. Others
  • 5.5.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Technology Business Analysis

• 6.1. Liquid Biopsy Market: Technology Movement Analysis
• 6.2. Multi-gene-parallel Analysis (NGS)
  • 6.2.1. Multi-gene-parallel Analysis (NGS) Market, 2021 - 2033 (USD Million)
• 6.3. Single Gene Analysis (PCR Microarrays)
  • 6.3.1. Single Gene Analysis (PCR Microarrays) Market, 2021 - 2033 (USD Million)

Chapter 7. Application Business Analysis

• 7.1. Liquid Biopsy Market: Application Movement Analysis
• 7.2. Cancer
  • 7.2.1. Cancer Market, 2021 - 2033 (USD Million)
    • 7.2.1.1. Lung Cancer
      • 7.2.1.1.1. Lung Cancer Market, 2021 - 2033 (USD Million)
    • 7.2.1.2. Prostate Cancer
      • 7.2.1.2.1. Prostate Cancer Market, 2021 - 2033 (USD Million)
    • 7.2.1.3. Breast Cancer
      • 7.2.1.3.1. Breast Cancer Market, 2021 - 2033 (USD Million)
    • 7.2.1.4. Colorectal Cancer
      • 7.2.1.4.1. Colorectal Cancer Market, 2021 - 2033 (USD Million)
    • 7.2.1.5. Leukemia
      • 7.2.1.5.1. Leukemia Market, 2021 - 2033 (USD Million)
    • 7.2.1.6. Gastrointestinal Cancer
      • 7.2.1.6.1. Gastrointestinal Cancer Market, 2021 - 2033 (USD Million)
    • 7.2.1.7. Others
      • 7.2.1.7.1. Others Market, 2021 - 2033 (USD Million)
• 7.3. Reproductive Health
  • 7.3.1. Reproductive Health Market, 2021 - 2033 (USD Million)
• 7.4. Others
  • 7.4.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. End Use Business Analysis

• 8.1. Liquid Biopsy Market: End-Use Movement Analysis
• 8.2. Hospitals and Laboratories
  • 8.2.1. Hospitals and Laboratories Market, 2021 - 2033 (USD Million)
• 8.3. Specialty Clinics
  • 8.3.1. Specialty Clinics Market, 2021 - 2033 (USD Million)
• 8.4. Academic and Research Centers
  • 8.4.1. Academic and Research Centers Market, 2021 - 2033 (USD Million)
• 8.5. Others
  • 8.5.1. Others Liquid Biopsy Market, 2021 - 2033 (USD Million)

Chapter 9. Clinical Application Business Analysis

• 9.1. Liquid Biopsy Market: Clinical Application Movement Analysis
• 9.2. Therapy Selection
  • 9.2.1. Therapy Selection Market, 2021 - 2033 (USD Million)
• 9.3. Treatment Monitoring
  • 9.3.1. Treatment Monitoring Market, 2021 - 2033 (USD Million)
• 9.4. Early Cancer Screening
  • 9.4.1. Early Cancer Screening Market, 2021 - 2033 (USD Million)
• 9.5. Recurrence Monitoring
  • 9.5.1. Recurrence Monitoring Market, 2021 - 2033 (USD Million)
• 9.6. Others
  • 9.6.1. Others Liquid Biopsy Market, 2021 - 2033 (USD Million)

Chapter 10. Product Business Analysis

• 10.1. Liquid Biopsy Market: Product Movement Analysis
• 10.2. Instruments
  • 10.2.1. Instruments Market, 2021 - 2033 (USD Million)
• 10.3. Consumables Kits and Reagents
  • 10.3.1. Consumables Kits and Reagents Market, 2021 - 2033 (USD Million)
• 10.4. Software and Services
  • 10.4.1. Software and Services Market, 2021 - 2033 (USD Million)

Chapter 11. Regional Business Analysis

• 11.1. Liquid Biopsy Market Share By Region, 2025 & 2033
• 11.2. North America
  • 11.2.1. North America Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.2.2. U.S.
    • 11.2.2.1. Key Country Dynamics
    • 11.2.2.2. Target Disease Prevalence
    • 11.2.2.3. Competitive Scenario
    • 11.2.2.4. Regulatory Framework
    • 11.2.2.5. Reimbursement Scenario
    • 11.2.2.6. U.S. Liquid biopsy market, 2021 - 2033 (USD MILLION)
  • 11.2.3. Canada
    • 11.2.3.1. Key Country Dynamics
    • 11.2.3.2. Target Disease Prevalence
    • 11.2.3.3. Competitive Scenario
    • 11.2.3.4. Regulatory Framework
    • 11.2.3.5. Reimbursement Scenario
    • 11.2.3.6. Canada Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.2.4. Mexico
    • 11.2.4.1. Key Country Dynamics
    • 11.2.4.2. Target Disease Prevalence
    • 11.2.4.3. Competitive Scenario
    • 11.2.4.4. Regulatory Framework
    • 11.2.4.5. Reimbursement Scenario
    • 11.2.4.6. Mexico Liquid biopsy market, 2021 - 2033 (USD Million)
• 11.3. Europe
  • 11.3.1. Europe Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.3.2. Germany
    • 11.3.2.1. Key Country Dynamics
    • 11.3.2.2. Target Disease Prevalence
    • 11.3.2.3. Competitive Scenario
    • 11.3.2.4. Regulatory Framework
    • 11.3.2.5. Reimbursement Scenario
    • 11.3.2.6. Germany Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.3.3. UK
    • 11.3.3.1. Key Country Dynamics
    • 11.3.3.2. Target Disease Prevalence
    • 11.3.3.3. Competitive Scenario
    • 11.3.3.4. Regulatory Framework
    • 11.3.3.5. Reimbursement Scenario
    • 11.3.3.6. UK Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.3.4. France
    • 11.3.4.1. Key Country Dynamics
    • 11.3.4.2. Target Disease Prevalence
    • 11.3.4.3. Competitive Scenario
    • 11.3.4.4. Regulatory Framework
    • 11.3.4.5. Reimbursement Scenario
    • 11.3.4.6. France Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.3.5. Italy
    • 11.3.5.1. Key Country Dynamics
    • 11.3.5.2. Target Disease Prevalence
    • 11.3.5.3. Competitive Scenario
    • 11.3.5.4. Regulatory Framework
    • 11.3.5.5. Reimbursement Scenario
    • 11.3.5.6. Italy Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.3.6. Spain
    • 11.3.6.1. Key Country Dynamics
    • 11.3.6.2. Target Disease Prevalence
    • 11.3.6.3. Competitive Scenario
    • 11.3.6.4. Regulatory Framework
    • 11.3.6.5. Reimbursement Scenario
    • 11.3.6.6. Spain Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.3.7. Denmark
    • 11.3.7.1. Key Country Dynamics
    • 11.3.7.2. Target Disease Prevalence
    • 11.3.7.3. Competitive Scenario
    • 11.3.7.4. Regulatory Framework
    • 11.3.7.5. Reimbursement Scenario
    • 11.3.7.6. Denmark Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.3.8. Sweden
    • 11.3.8.1. Key Country Dynamics
    • 11.3.8.2. Target Disease Prevalence
    • 11.3.8.3. Competitive Scenario
    • 11.3.8.4. Regulatory Framework
    • 11.3.8.5. Reimbursement Scenario
    • 11.3.8.6. Sweden Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.3.9. Norway
    • 11.3.9.1. Key Country Dynamics
    • 11.3.9.2. Target Disease Prevalence
    • 11.3.9.3. Competitive Scenario
    • 11.3.9.4. Regulatory Framework
    • 11.3.9.5. Reimbursement Scenario
    • 11.3.9.6. Norway Liquid biopsy market, 2021 - 2033 (USD Million)
• 11.4. Asia Pacific
  • 11.4.1. Asia Pacific Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.4.2. Japan
    • 11.4.2.1. Key Country Dynamics
    • 11.4.2.2. Target Disease Prevalence
    • 11.4.2.3. Competitive Scenario
    • 11.4.2.4. Regulatory Framework
    • 11.4.2.5. Reimbursement Scenario
    • 11.4.2.6. Japan Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.4.3. China
    • 11.4.3.1. Key Country Dynamics
    • 11.4.3.2. Target Disease Prevalence
    • 11.4.3.3. Competitive Scenario
    • 11.4.3.4. Regulatory Framework
    • 11.4.3.5. Reimbursement Scenario
    • 11.4.3.6. China Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.4.4. India
    • 11.4.4.1. Key Country Dynamics
    • 11.4.4.2. Target Disease Prevalence
    • 11.4.4.3. Competitive Scenario
    • 11.4.4.4. Regulatory Framework
    • 11.4.4.5. Reimbursement Scenario
    • 11.4.4.6. India Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.4.5. South Korea
    • 11.4.5.1. Key Country Dynamics
    • 11.4.5.2. Target Disease Prevalence
    • 11.4.5.3. Competitive Scenario
    • 11.4.5.4. Regulatory Framework
    • 11.4.5.5. Reimbursement Scenario
    • 11.4.5.6. South Korea Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.4.6. Australia
    • 11.4.6.1. Key Country Dynamics
    • 11.4.6.2. Target Disease Prevalence
    • 11.4.6.3. Competitive Scenario
    • 11.4.6.4. Regulatory Framework
    • 11.4.6.5. Reimbursement Scenario
    • 11.4.6.6. Australia Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.4.7. Thailand
    • 11.4.7.1. Key Country Dynamics
    • 11.4.7.2. Target Disease Prevalence
    • 11.4.7.3. Competitive Scenario
    • 11.4.7.4. Regulatory Framework
    • 11.4.7.5. Reimbursement Scenario
    • 11.4.7.6. Thailand Liquid biopsy market, 2021 - 2033 (USD Million)
• 11.5. Latin America
  • 11.5.1. Latin America Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.5.2. Brazil
    • 11.5.2.1. Key Country Dynamics
    • 11.5.2.2. Target Disease Prevalence
    • 11.5.2.3. Competitive Scenario
    • 11.5.2.4. Regulatory Framework
    • 11.5.2.5. Reimbursement Scenario
    • 11.5.2.6. Brazil Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.5.3. Argentina
    • 11.5.3.1. Key Country Dynamics
    • 11.5.3.2. Target Disease Prevalence
    • 11.5.3.3. Competitive Scenario
    • 11.5.3.4. Regulatory Framework
    • 11.5.3.5. Reimbursement Scenario
    • 11.5.3.6. Argentina Liquid biopsy market, 2021 - 2033 (USD Million)
• 11.6. Middle East and Africa
  • 11.6.1. Middle East and Africa Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.6.2. South Africa
    • 11.6.2.1. Key Country Dynamics
    • 11.6.2.2. Target Disease Prevalence
    • 11.6.2.3. Competitive Scenario
    • 11.6.2.4. Regulatory Framework
    • 11.6.2.5. Reimbursement Scenario
    • 11.6.2.6. South Africa Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.6.3. Saudi Arabia
    • 11.6.3.1. Key Country Dynamics
    • 11.6.3.2. Target Disease Prevalence
    • 11.6.3.3. Competitive Scenario
    • 11.6.3.4. Regulatory Framework
    • 11.6.3.5. Reimbursement Scenario
    • 11.6.3.6. Saudi Arabia Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.6.4. UAE
    • 11.6.4.1. Key Country Dynamics
    • 11.6.4.2. Target Disease Prevalence
    • 11.6.4.3. Competitive Scenario
    • 11.6.4.4. Regulatory Framework
    • 11.6.4.5. Reimbursement Scenario
    • 11.6.4.6. UAE Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.6.5. Kuwait
    • 11.6.5.1. Key Country Dynamics
    • 11.6.5.2. Target Disease Prevalence
    • 11.6.5.3. Competitive Scenario
    • 11.6.5.4. Regulatory Framework
    • 11.6.5.5. Reimbursement Scenario
    • 11.6.5.6. Kuwait Liquid biopsy market, 2021 - 2033 (USD Million)

Chapter 12. Competitive Landscape

• 12.1. Participant's overview
• 12.2. Financial performance
• 12.3. Participant categorization
  • 12.3.1. Market Leaders
  • 12.3.2. Liquid Biopsy Market Share Analysis, 2025
  • 12.3.3. Company Profiles
    • 12.3.3.1. ANGLE plc
      • 12.3.3.1.1. Company Overview
      • 12.3.3.1.2. Financial Performance
      • 12.3.3.1.3. Product Benchmarking
      • 12.3.3.1.4. Strategic Initiatives
    • 12.3.3.2. Oncimmune Holdings PLC
      • 12.3.3.2.1. Company Overview
      • 12.3.3.2.2. Financial Performance
      • 12.3.3.2.3. Product Benchmarking
      • 12.3.3.2.4. Strategic Initiatives
    • 12.3.3.3. Guardant Health
      • 12.3.3.3.1. Company Overview
      • 12.3.3.3.2. Financial Performance
      • 12.3.3.3.3. Product Benchmarking
      • 12.3.3.3.4. Strategic Initiatives
    • 12.3.3.4. Myriad Genetics, Inc.
      • 12.3.3.4.1. Company Overview
      • 12.3.3.4.2. Financial Performance
      • 12.3.3.4.3. Product Benchmarking
      • 12.3.3.4.4. Strategic Initiatives
    • 12.3.3.5. Biocept, Inc.
      • 12.3.3.5.1. Company Overview
      • 12.3.3.5.2. Financial Performance
      • 12.3.3.5.3. Product Benchmarking
      • 12.3.3.5.4. Strategic Initiatives
    • 12.3.3.6. Lucence Health Inc.
      • 12.3.3.6.1. Company Overview
      • 12.3.3.6.2. Financial Performance
      • 12.3.3.6.3. Product Benchmarking
      • 12.3.3.6.4. Strategic Initiatives
    • 12.3.3.7. Freenome Holdings, Inc.
      • 12.3.3.7.1. Company Overview
      • 12.3.3.7.2. Financial Performance
      • 12.3.3.7.3. Product Benchmarking
      • 12.3.3.7.4. Strategic Initiatives
    • 12.3.3.8. F. Hoffmann-La Roche Ltd.
      • 12.3.3.8.1. Company Overview
      • 12.3.3.8.2. Financial Performance
      • 12.3.3.8.3. Product Benchmarking
      • 12.3.3.8.4. Strategic Initiatives
    • 12.3.3.9. QIAGEN
      • 12.3.3.9.1. Company Overview
      • 12.3.3.9.2. Financial Performance
      • 12.3.3.9.3. Product Benchmarking
      • 12.3.3.9.4. Strategic Initiatives
    • 12.3.3.10. Illumina, Inc.
      • 12.3.3.10.1. Company Overview
      • 12.3.3.10.2. Financial Performance
      • 12.3.3.10.3. Product Benchmarking
      • 12.3.3.10.4. Strategic Initiatives
    • 12.3.3.11. Thermo Fisher Scientific, Inc.
      • 12.3.3.11.1. Company Overview
      • 12.3.3.11.2. Financial Performance
      • 12.3.3.11.3. Product Benchmarking
      • 12.3.3.11.4. Strategic Initiatives
    • 12.3.3.12. Epigenomics AG
      • 12.3.3.12.1. Company Overview
      • 12.3.3.12.2. Financial Performance
      • 12.3.3.12.3. Product Benchmarking
      • 12.3.3.12.4. Strategic Initiatives
  • 12.3.4. Strategy Mapping
    • 12.3.4.1. Expansion
    • 12.3.4.2. Acquisition
    • 12.3.4.3. Collaborations
    • 12.3.4.4. Disease Type/Drug Class Launch
    • 12.3.4.5. Partnerships
    • 12.3.4.6. Others